Nido Biosciences, Inc.

Developing small molecules to treat neurodegenerative disease

Nido Biosciences is a clinical stage biotech company started in Cambridge, MA in 2019 by scientific co-founders J. Paul Taylor and Junying Yuan. Led by an experienced team including Jeremy Springhorn (CEO) and Vissia Viglietta (CMO), the company is developing synthesized bicyclic compounds acting as selective androgen receptor modulators (SARMs) for the treatment of spinal and bulbar muscular atrophy (SBMA). In addition, Nido Biosciences is building a pipeline of assets for rare and common neurodegenerative disease based on a best-in-class screening platform that enables identification of modulators of neurodegenerative disease biology using iPSC-derived neuronal cells from patients.